Regenerative Medicine Disability Research lab, Department of Biomedical Science, UIC College of Medicine at Rockford, Rockford, IL, United States.
Regenerative Medicine Disability Research lab, Department of Biomedical Science, UIC College of Medicine at Rockford, Rockford, IL, United States.
Int J Biol Macromol. 2023 Dec 31;253(Pt 4):126681. doi: 10.1016/j.ijbiomac.2023.126681. Epub 2023 Sep 2.
Breast cancer is the second highest cause of cancer-related mortality in women worldwide and in the United States, accounting for around 571,000 deaths per year. Early detection of breast cancer increases treatment results and the possibility of a cure. While existing diagnostic modalities such as mammography, ultrasound, and biopsy exist, some are prohibitively expensive, uncomfortable, time-consuming, and have limited sensitivity, necessitating the development of a cost-effective, rapid, and highly sensitive approach such as an electrochemical biosensor. Our research focuses on detecting breast cancer patients using the ECM1 biomarker, which has higher expression in synthetic urine. Our study has two primary objectives: (i) Diverse ECM1 protein concentrations are measured using electrochemical impedance spectroscopy and ELISA. Establishing a standard curve for the electrochemical biosensor by calibrating ECM-1 protein levels using electrochemical impedance spectroscopy. (ii) Validation of the effectiveness of the electrochemical biosensor. This aim entails testing the unknown concentration of ECM1 in the synthetic urine to ensure the efficiency of the biosensor to detect the biomarker in the early stages. The results show that the synthetic urine solution's ECM-1 detection range ranges from 1 pg/ml to 500 ng/ml. This shows that by detecting changes in ECM-1 protein levels in patient urine, the electrochemical biosensor can consistently diagnose breast cancer in its early stages or during increasing recurrence. Our findings highlight the electrochemical biosensor's efficacy in detecting early-stage breast cancer biomarkers (ECM-1) in patient urine. Further studies will be conducted with patient samples and develop handheld hardware for patient usage.
乳腺癌是全球和美国女性癌症相关死亡率第二高的原因，每年导致约 571,000 人死亡。早期发现乳腺癌可提高治疗效果和治愈的可能性。虽然存在乳腺 X 线摄影、超声和活检等现有的诊断方式，但有些方式价格昂贵、不舒服、耗时且敏感性有限，因此需要开发一种具有成本效益、快速且高度敏感的方法，例如电化学生物传感器。我们的研究专注于使用 ECM1 生物标志物检测乳腺癌患者，该标志物在合成尿液中的表达更高。我们的研究有两个主要目标：(i) 使用电化学阻抗谱和 ELISA 测量不同的 ECM1 蛋白浓度。通过使用电化学阻抗谱校准 ECM-1 蛋白水平，为电化学生物传感器建立标准曲线。(ii) 验证电化学生物传感器的有效性。这一目标需要测试合成尿液中未知浓度的 ECM1，以确保生物传感器能够在早期检测到生物标志物。结果表明，合成尿液溶液的 ECM-1 检测范围为 1 pg/ml 至 500 ng/ml。这表明通过检测患者尿液中 ECM-1 蛋白水平的变化，电化学生物传感器可以持续诊断早期或复发期乳腺癌。我们的研究结果突出了电化学生物传感器在检测患者尿液中早期乳腺癌生物标志物（ECM-1）方面的功效。将进一步进行患者样本的研究，并开发用于患者使用的手持硬件。
